Welcome to the Bioprinting Short Course (~3 hrs)
Join the Biocovergence Revolution
Bioprinting has come to the forefront of regenerative medicine and tissue engineering due to the increasing need for human organs for transplantation. According to the United Network for Organ Sharing (UNOS), a staggering 100,000 patients are currently waiting for organ transplants. By printing human cells in physiologically relevant geometries, with materials that mimic the native cellular environment, 3D bioprinting technology has risen as an exceptional solution to this problem, bringing researchers one step closer to meeting the growing need for transplantable organs.
In this course, you will be introduced to the basics of extrusion and light-based bioprinting. You will learn how this novel technology can be used to print tissue models mimicking the innate cellular environment and be introduced to some of the most common applications.
At the end of this course, you will be able to:
- Describe the basic concepts underlying the design of a successful bioprinting experiment.
- List the key considerations in developing a functional biomaterial for bioprinting.
- Identify different bioprinting methods.
- Print basic structures using the BIO X and LUMEN X.
We hope you enjoy this course, but more importantly, we hope you enjoy your day! Have fun!
CELLINK is creating the future of health as part of BICO, the world’s leading bioconvergence company. When it released the first universal bioink in 2016, CELLINK democratized the cost of entry for researchers around the world and played a major role in turning the then up-and-coming field of 3D bioprinting into a thriving $1 billion industry. Today, the company’s best-in-class bioinks, bioprinters, software and services have been cited in over 700 publications and are trusted by more than 1,000 academic, pharmaceutical and industrial labs. At the forefront of the bioprinting industry, CELLINK aims to alleviate organ donor shortage with biofabricated transplantable organs and remains committed to reducing our dependence on animal testing and increasing efficiencies in drug development with more physiologically relevant bioprinted organ models. Read more at www.cellink.com